AKT1 and cancer: TQ-B3525, a novel PI3Kδ/α dual inhibitor developed by Zhengda Tianqing, induces cell apoptosis and inhibits the proliferation of malignant tumor cells by inhibiting the expression of PI3K protein and reducing the phosphorylation level of AKT protein (Li et al., 2024).